Literature DB >> 7299695

Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.

J J Lima, H Boudoulas, M Blanford.   

Abstract

Disopyramide binds to two independent sites on protein in human plasma. The first binding site located on alpha-1-acid glycoprotein has an association and a capacity constant of 1.0 x 10(6) M-1 and 3.5 x 10(-6) M, respectively, and accounts for the majority of disopyramide binding. The second site is probably located on albumin and accounts for 5 to 10% of the binding. The bound fraction of disopyramide was concentration-dependent at drug concentrations reported to be therapeutic. After administration of 100, 150, 200 and 300 mg doses of disopyramide (Norpace) to each of four human volunteers, the area under the free (unbound) disopyramide serum-concentration time curve averaged 2.32, 3.33, 5.21 and 8.24 mg/l. hr, respectively, and was directly proportional to dose. The elimination half-lives based on free and total drug concentrations averaged 4.36 and 6.51 hr, respectively (P less than .001), and were dose-independent. The peak response (change in pre-ejection period) and area under the response time curves were better related to free than to total serum concentrations of disopyramide.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7299695

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Role of biantennary glycans and genetic variants of human alpha1-acid glycoprotein in enantioselective binding of basic drugs as studied by high performance frontal analysis/capillary electrophoresis.

Authors:  Y Kuroda; Y Kita; A Shibukawa; T Nakagawa
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 4.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 5.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

6.  Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.

Authors:  H Echizen; M Nakura; T Saotome; S Minoura; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

7.  Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

8.  Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.

Authors:  H Echizen; S Saima; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

9.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

10.  Kinetics of disopyramide in decreased hepatic function.

Authors:  J Bonde; N A Graudal; L E Pedersen; S Balsløv; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.